Kifah Blal

Dr. Kifah Blal

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 January 2023 in Cancers
Verified
Journal Article
Open access
PDF file
Kifah BlalKifah Blal
Kifah Blal
EBElazar Besser
Elazar Besser
SPShiri Procaccia
Shiri Procaccia
OSOuri Schwob
Ouri Schwob
YLYaniv Lerenthal
Yaniv Lerenthal
Ofra BennyOfra Benny
Ofra Benny
Cannabis sativa plants have a wide diversity in their metabolite composition among their different chemovars, facilitating diverse anti-tumoral effects on cancer cells. This research examined the anti-tumoral effects of 24 cannabis extracts representative of three primary types of chemovars on head and neck squamous cell carcinoma (HNSCC). The chemical composition of the extracts was determined using High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). The most potent anti-tumoral extracts were type III decarboxylated extracts, with high levels of Cannabidiol (CBD). We identified extract 296 (CAN296) as the most potent in inducing HNSCC cell death via proapoptotic and anti-proliferative effects. Using chemical fractionation of CAN296, we identified the CBD fraction as the primary inducer of the anti-tumoral activity. We succeeded in defining the combination of CBD with cannabichromene (CBC) or tetrahydrocannabinol (THC) present in minute concentrations in the extract, yielding a synergic impact that mimics the extract’s full effect. The cytotoxic effect could be maximized by combining CBD with either CBC or THC in a ratio of 2:1. This research suggests using decarboxylated CBD-type extracts enriched with CBC for future preclinical trials aimed at HNSCC treatment.

1 August 2020 in International Journal of Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
Kifah BlalKifah Blal
Kifah Blal
MAM. Alterman
M. Alterman
JTJ. Abu Tair
J. Abu Tair

Verified
Journal Article
Open access
PDF file
Kifah BlalKifah Blal
Kifah Blal
RRRonen Rosenblum
Ronen Rosenblum
HNHila Novak-Kotzer
Hila Novak-Kotzer
SPShiri Procaccia
Shiri Procaccia
JTJawad Abu Tair
Jawad Abu Tair
Ofra BennyOfra Benny
Ofra Benny
This study investigates the immunomodulatory effects of a well-characterized cannabidiol (CBD)-rich cannabis extract, CAN296, on T lymphocytes (T cells), particularly Cluster of Differentiation 4 (CD4+) helper and Cluster of Differentiation 8 (CD8+) cytotoxic subsets, by examining T-cell activation, cytokine secretion, and cytotoxic molecule expression in comparison with the conventional treatments dexamethasone (DEX) and tacrolimus (TAC). It addresses key processes involved in the formation of premalignant immune-mediated lesions, such as those seen in oral lichen planus (OLP) and oral manifestations of graft-versus-host disease (oGVHD). CD4+ and CD8+ T cells were isolated from healthy donors and assessed in vitro for T cell activation via CD69 expression, secreted tumor necrosis factor alpha (TNF-α) and interferon gamma (IFN-γ) levels according to enzyme-linked immunosorbent assay (ELISA), and cytotoxic molecule expression Granzyme B, Perforin, Fas Ligand (Fas-L) quantified by flow cytometry. Cells were treated with different doses of CAN296 (2, 4, 8 µg/mL), DEX (0.4, 4, 40 µg/mL), or TAC (0.1, 1, 10 ng/mL), and all parameters were compared to untreated controls. CAN296 significantly inhibited T cell activation, reducing CD69 expression in CD4+ T cells to 2–11% and in CD8+ T cells to 5–17%. It also markedly suppressed TNF-α secretion in CD4+ T cells at all concentrations (p < 0.0001). In CD8+ T cells, CAN296 led to a near-complete reduction in TNF-α and IFN-γ, leaving both cytokines barely detectable at all tested doses (p < 0.0001). The effect of cell inhibition was significantly more pronounced than that observed with DEX or TAC, displaying dose-dependent reductions. TAC inconsistently lowered TNF-α while paradoxically increasing IFN-γ at lower concentrations. Additionally, CAN296 consistently suppressed cytotoxic molecule expression, reducing Granzyme B by 81–82%, Perforin by 40–53%, and Fas-L by 40–44%. DEX showed variable effects on cytotoxic molecule expression. At the same time, TAC demonstrated inconsistent modulation of Perforin and Granzyme B. Overall, CAN296 outperformed DEX and TAC, demonstrating more potent and consistent immunomodulatory effects. CBD-rich cannabis extract, CAN296, exhibits potent immunomodulatory properties by effectively inhibiting T cell activation, lowering pro-inflammatory cytokines, and suppressing cytotoxic molecule expression. Its efficacy surpasses conventional therapies like DEX and TAC, offering a promising novel treatment modality for T cell-mediated disorders, including OLP and oGVHD. These findings support further development of CAN296 formulations to optimize dosing and delivery, followed by clinical trials to validate its therapeutic potential.

Verified
Journal Article
Open access
PDF file
Kifah BlalKifah Blal
Kifah Blal
GMGeorgette Maroukian
Georgette Maroukian
ASAnna Shapira
Anna Shapira
SPShiri Procaccia
Shiri Procaccia
DMDavid Meiri
David Meiri
Ofra BennyOfra Benny
Ofra Benny
The cannabidiol (CBD)-rich cannabis extract CAN296 shows anti-inflammatory and anticancer activity relevant to oral lichen planus (OLP), oral graft-versus-host disease (oGVHD), and oral squamous cell carcinoma (OSCC), but its high lipophilicity limits aqueous dispersion. This study developed a stable Tween-based nanoemulsion optimized for oral mucosal delivery. Ethanol-dissolved CAN296 was nanoemulsified using a 1% Tween/Span system. Physical stability was visually assessed; droplet size and morphology were examined by dynamic light scattering (DLS) and transmission electron microscopy (TEM); and wettability was measured by static contact angle (SCA). Additional evaluations included temperature stability (25 °C vs. 4 °C), in vitro release using a dialysis membrane, and scanning electron microscopy (SEM) of membrane-associated droplets. Nanoemulsions with ≥80% Tween 80 incorporated CAN296 up to 800 µg/mL, clear at 400 µg/mL, and uniformly turbid at 800 µg/mL. DLS and TEM confirmed spherical nanoscale droplets, and SCA indicated favorable cohesion and wettability. Stability was maintained for 30 days at 4 °C. Dialysis studies demonstrated strong membrane association with limited diffusion, supported by SEM visualization of membrane-bound droplets. The Tween-dominant (≥80%) nanoemulsion stably incorporated CAN296 up to 800 µg/mL, demonstrated nanoscale uniformity, improved 4 °C stability, and strong membrane retention under static conditions, suggesting potential for localized oral delivery.


12 November 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Kifah BlalKifah Blal
Kifah Blal
GMGeorgette Maroukian
Georgette Maroukian
ASAnna Shapira
Anna Shapira
SPShiri Procaccia
Shiri Procaccia
DMDavid Meiri
David Meiri
Ofra BennyOfra Benny
Ofra Benny
Background/Objectives: The cannabidiol (CBD)-rich cannabis extract (CAN296) exhibits potent anti-inflammatory and anticancer activity with a favorable safety profile, making it a promising candidate for the management of inflammatory, precancerous, and malignant conditions, particularly for diseases with limited treatment options such as oral lichen planus (OLP), oral manifestations of graft-versus-host disease (oGVHD), and oral squamous cell carcinoma (OSCC). However, cannabis extracts in general, including CAN296, are characterized by high lipophilicity and poor aqueous solubility, which pose significant challenges to formulation stability and bioavailability. This study aimed to develop a stable Tween-based nanoemulsion of cannabis extract optimized for oral mucosal delivery. Methods: Ethanol-dissolved cannabis extract was nanoemulsified with Tween 80/Span 80 surfactant blends at varying concentrations up to 4000 µg/mL and 1% total surfactant. Formulations were visually inspected for physical stability over an 8-week period. Selected emulsions were analyzed by dynamic light scattering (DLS) for droplet size and polydispersity and by transmission electron microscopy (TEM) for morphology. Additional assays included static contact angle (SCA) measurements for wettability, temperature-dependent stability testing (at 25 °C vs. 4 °C for 30 days), and an in vitro release study using a dialysis membrane, complemented by scanning electron microscopy (SEM) to visualize droplet deposition on the membrane surface. Results: Nanoemulsions containing ≥80% Tween 80 (1% surfactant) successfully incorporated cannabis extract up to 800 µg/mL, clear at 400 µg/mL, and turbid but homogeneous at 800 µg/mL, forming stable dispersions with improved nanoscale uniformity. DLS and TEM confirmed uniform spherical morphology, while SCA analysis indicated optimal droplet cohesion and wettability. Storage stability was maintained for 30 days at 4 °C, and in vitro dialysis studies revealed strong membrane association with limited diffusion, further supported by SEM visualization of membrane-bound aggregates. These findings suggest a favorable mucoadhesive potential for oral application. Conclusion: A Tween-dominant (≥80%) nanoemulsion stably incorporated CBD-rich extracts up to 800 µg/mL, well above therapeutic levels. The optimized system showed nanoscale uniformity, improved stability at 4 °C, and significant membrane retention, supporting its potential as a mucoadhesive platform for targeted oral delivery in immune-mediated and precancerous conditions.